MiRNA based treatment monitoring in multiple sclerosis

US10428382B2 · kind B2 · utility

Assignee

• Hummingbird Diagnostics GmbH · DE

Inventors

• Andreas Keller · Ettlingen, DE
• Markus Beier · Heidelberg, DE
• Matthias Scheffler · Leutershausen, DE
• Anke Wendschlag · Mannheim, DE
• Orhan Aktas · Hilden, DE
• Jens Ingwersen · Düsseldorf, DE
• Hans-Peter Hartung · Düsseldorf, DE
• Patrick Küry · Langendorf, CH
• Timour Prozorovski · Düsseldorf, DE

Key dates

• Filing date: Mar 7, 2013
• Grant date: Oct 1, 2019
• Expiry date: Mar 7, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/178
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient. Further, the present invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of multiple sclerosis, to monitor the course of multiple sclerosis in a patient, to determine the risk of a relapse of multiple sclerosis in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, and to identify a compound suitable for the treatment of multiple sclerosis in a patient. Furt…